Overview

Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections

Status:
NOT_YET_RECRUITING
Trial end date:
2029-12-01
Target enrollment:
Participant gender:
Summary
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infection in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy
Phase:
PHASE3
Details
Lead Sponsor:
Octapharma
Treatments:
Panzyga